ClinicalTrials.gg
CompletedNCT01943903PLATFORMUpdated Sep 5, 2025Results posted

The PLATFORM Study: Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts)

An observational study in Coronary Artery Disease, sponsored by HeartFlow, Inc.. Completed at 15 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by HeartFlow, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
584
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Coronary Artery Disease by HeartFlow, Inc. — 4 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · HeartFlow, Inc..

Started
2013
the only one that year
Observational
7 of 12
2 open now
Registered
3rd of 12
by date

Among the 12 studies in Coronary Artery Disease by HeartFlow, Inc., this one is the only one that started in 2013, is one of 7 observational ones, and was the 3rd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

4 of the 12 studies in Coronary Artery Disease by HeartFlow, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Coronary Artery Disease by HeartFlow, Inc., or all of them as a file.
02

Study summary

The objective of the PLATFORM Study is to compare clinical outcomes, resource utilization, and quality of life (QOL) of FFRCT-guided evaluation versus standard practice evaluation in patients with suspected CAD in order to further inform patients, health care providers, and other stakeholders about which technologies are most effective and efficient in the diagnosis of CAD

Read the detailed description

The OVERALL OBJECTVE of this post-market, multicenter, longitudinal, prospective, consecutive cohort study is to compare clinical outcomes, resource utilization, and quality of life (QOL) in subjects receiving standard practice evaluation and treatment versus subjects receiving FFRCT-guided evaluation and treatment in subjects with suspected CAD in order to further inform patients, health care providers, and other stakeholders about which technologies are most effective and efficient in the diagnosis of CAD. Cohort 1 of this study will assess outcomes incorporating standard practice evaluation and Cohort 2 will assess outcomes incorporating FFRCT-guided evaluation. Each Cohort will be further delineated based upon initial presentation, whereas subjects presenting for initial non-invasive testing will be designated as Cohorts 1A and 2A; and subjects already referred for ICA will be designated as Cohorts 1B and 2B.

SPECIFIC OBJECTIVES for sequential cohort comparisons:

  1. To compare the rate of ICA documenting non-obstructive coronary artery disease, clinical outcomes, and QOL following standard practice for diagnostic and treatment planning modalities in Cohort 1 versus incorporating FFRCT as the preferred test to guide further invasive management and medical treatment in Cohort 2;
  2. To compare resource utilization following standard practice for diagnostic and treatment pathways in Cohort 1 versus incorporating FFRCT as the preferred test to guide further invasive management and medical treatment in Cohort 2;
  3. To provide supporting data for generating new guidelines for diagnosis and prognosis of CAD with comparative analysis of the risk stratification with the Updated Diamond-Forrester risk model (UDF);
  4. To provide society including patients, health care providers and other stakeholders with information about which diagnostic technologies are most effective and efficient in managing patients with CAD.
03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects referred with intermediate likelihood of obstructive CAD with an Updated Diamond-Forrester (UDF) risk score 20-80% with symptomatic, suspected CAD

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Providing written
  • Subjects with intermediate likelihood of obstructive CAD with an Updated Diamond-Forrester (UDF) risk score 20-80% with symptomatic, suspected CAD who:
  • In Cohort 1A \& 2A only are scheduled to undergo initial clinically-indicated non-invasive coronary evaluation, and have not undergone non-invasive coronary evaluation, including exercise tolerance testing, stress echocardiography, SPECT or MRI, or cCTA, within the past 90 days OR ICA at any time; or
  • In Cohort 1B \& 2B only have been referred to invasive coronary angiography (ICA) and have not undergone ICA within the past 90 days
  • Ability to undergo cCTA

Exclusion criteria

Exclusion Criteria:

  • Suspicion of acute coronary syndrome. Subjects experiencing unstable angina are not excluded where clinical documentation has ruled out a myocardial infarction.
  • Prior, clinically documented myocardial infarction
  • PCI prior to first test
  • CABG prior to first test
  • for cCTA such as:
  • Presence of pacemaker or internal defibrillator leads
  • Atrial Fibrillation
  • Known anaphylactic allergy to iodinated contrast
  • Pregnancy or unknown pregnancy status in women of
  • >35 kg/m2
  • Contraindication to acute beta blockade
  • Contraindication to acute sublingual nitrate administration
  • Prosthetic heart valve
  • Contraindications to FFRCT
  • Complex Congenital Heart disease other than anomalous coronary origins alone
  • Ventricular septal defect with known Qp/Qs>1.4
  • Requiring an emergent procedure within 48 hours of presentation
  • Evidence of active clinical instability, including cardiogenic shock, unstable blood pressure with systolic blood pressure \<90 mmHg, or Grade III or IV congestive heart failure or acute pulmonary edema
  • Any active, serious, life-threatening disease with a of less than 2 years
  • Inability to comply with study follow-up requirements
  • Current participation in any other clinical trial involving an device or dictating care pathways at the time of enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
584 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1 - Standard of Care

    Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of each subject considered for percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), the investigator and the institution's heart team will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice. Cohort 1 of the study is an observational evaluation of resource utilization and outcomes based on standard practice for diagnosis and treatment of subjects with symptomatic suspected CAD and intermediate likelihood of obstructive CAD. Subjects will be followed for one year after enrollment.

  • Cohort 2 - FFRCT-guided

    Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of subjects considered for PCI and/or CABG, the investigator and the institution's heart team will review the results of all available diagnostic tests, including cCTA and FFRCT, and will recommend a treatment strategy accordingly. FFRCT is a non-invasive method to evaluate the hemodynamic significance of coronary artery lesions. FFRCT calculates FFR from subject-specific cCTA data using computational fluid dynamics under rest and simulated maximal coronary hyperemic conditions. FFRCT values range between 0 and 1, and values ≤0.80 are considered hemodynamically (HD)-significant.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Negative Invasive Coronary Angiography

    The primary endpoint of the PLATFORM Study is 90 day (+30/-15 days) rate of coronary angiogram showing no stenosis \> 50% in a vessel \> 2.0 mm by Quantitative Coronary Angiography (QCA), or no invasively-measured FFR \< 0.80 in a segment distal to a stenosis in a vessel \> 2.0 mm by QCA between Cohort 1 and 2.

    Time frame: 90 Days from first test

Secondary outcomes

  1. Number of MACE

    90 days (+30/-30 days) Cohort 1 and Cohort 2 Major Adverse Coronary Event (MACE) rates, defined as: 1. All cause death 2. Non-fatal MI 3. Unplanned hospitalization for acute coronary syndrome (ACS) leading to urgent revascularization

    Time frame: 90 days from first test

  2. Number of MACE or Vascular Complications

    90 days (+30/-30 days) Major Adverse Coronary Event (MACE) rates, defined as: all cause death, non-fatal MI, unplanned hospitalization for acute coronary syndrome (ACS) leading to urgent revascularization and vascular complications (related to any coronary testing or procedure).This secondary endpoint compared the rates of MACE and vascular events across all subjects in Cohort 1 vs Cohort 2, Cohort 1A vs Cohort 2A and Cohort 1B vs Cohort 2B. The rates of MACE and vascular events were calculated by dividing the number of subjects with MACE and vascular events by the total number of subjects assigned to each analysis population.

    Time frame: 90 days from first test

  3. Number of Participants With Resource (CV Test Types Performed) Utilization at 90 Days

    Comparison of Resource utilization between cohort 1 and cohort 2 at 90 days (+/- 30 days): 1. Non-invasive diagnostic tests 2. Invasive diagnostic tests 3. Coronary revascularization procedures

    Time frame: 90 days from first test

  4. Number of Participants With Medications Used by Type

    Comparison of medication use between cohort 1A, 1B and cohort 2A, 2B at 90 days (+/- 15 days)

    Time frame: at 90 days

07

Results

Posted Sep 5, 2025

Participant flow

Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of each subject considered for percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), the investigator and the institution's heart team will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice.

Participant flow — Overall Study
MilestoneNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTInvasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCT
Started100104187193
Completed100104187193
Not completed0000

Outcome measures

PrimaryNumber of Participants With Negative Invasive Coronary Angiography

The primary endpoint of the PLATFORM Study is 90 day (+30/-15 days) rate of coronary angiogram showing no stenosis \> 50% in a vessel \> 2.0 mm by Quantitative Coronary Angiography (QCA), or no invasively-measured FFR \< 0.80 in a segment distal to a stenosis in a vessel \> 2.0 mm by QCA between Cohort 1 and 2.

Time frame:
90 Days from first test
Reported as:
Count of participants · Participants
Number of Participants With Negative Invasive Coronary Angiography
ParticipantsPlanned Invasive Test Usual Care Strategy (Cohort 1B)Planned Invasive Test FFRCT Guided Strategy (Cohort 2B)
Number of Participants With Negative Invasive Coronary Angiography13724
SecondaryNumber of MACE

90 days (+30/-30 days) Cohort 1 and Cohort 2 Major Adverse Coronary Event (MACE) rates, defined as: 1. All cause death 2. Non-fatal MI 3. Unplanned hospitalization for acute coronary syndrome (ACS) leading to urgent revascularization

Time frame:
90 days from first test
Reported as:
Count of participants · Participants
Number of MACE
ParticipantsNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTInvasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCT
Number of MACE1022
SecondaryNumber of MACE or Vascular Complications

90 days (+30/-30 days) Major Adverse Coronary Event (MACE) rates, defined as: all cause death, non-fatal MI, unplanned hospitalization for acute coronary syndrome (ACS) leading to urgent revascularization and vascular complications (related to any coronary testing or procedure).This secondary endpoint compared the rates of MACE and vascular events across all subjects in Cohort 1 vs Cohort 2, Cohort 1A vs Cohort 2A and Cohort 1B vs Cohort 2B. The rates of MACE and vascular events were calculated by dividing the number of subjects with MACE and vascular events by the total number of subjects assigned to each analysis population.

Time frame:
90 days from first test
Reported as:
Count of participants · Participants
Number of MACE or Vascular Complications
ParticipantsNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTInvasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCT
Number of MACE or Vascular Complications0127
SecondaryNumber of Participants With Resource (CV Test Types Performed) Utilization at 90 Days

Comparison of Resource utilization between cohort 1 and cohort 2 at 90 days (+/- 30 days): 1. Non-invasive diagnostic tests 2. Invasive diagnostic tests 3. Coronary revascularization procedures

Time frame:
90 days from first test
Reported as:
Count of participants · Participants
Number of Participants With Resource (CV Test Types Performed) Utilization at 90 Days
ParticipantsNon-invasive (Cohort 1A) Usual CareNon-invasive Cohort (Cohort 2A) FFRCTInvasive Cohort (Cohort 1B) Usual CareInvasive Cohort (Cohort 2B) FFRCT
ECG235932
Stress Echo2076
Nuclear/Stress MPI/CMR32235
cCTA without FFRCT822112
cCTA with FFRCT017064
IVUS, OCT, or FFR371730
ICA121918776
PCI394245
CABG211710
SecondaryNumber of Participants With Medications Used by Type

Comparison of medication use between cohort 1A, 1B and cohort 2A, 2B at 90 days (+/- 15 days)

Time frame:
at 90 days
Reported as:
Number · participants (total count)
Number of Participants With Medications Used by Type
participants (total count)Non-invasive (Cohort 1A) Usual CareNon-invasive Cohort (Cohort 2A) FFRCTInvasive Cohort (Cohort 1B) Usual CareInvasive Cohort (Cohort 2B) FFRCT
Aspirin294511590
Statin24298377

Adverse events

Collected over Clinical Outcomes at 1 Year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-invasive (Cohort 2) Usual Care0/100 (0%)2/100 (2%)6/100 (6%)
Non-invasive Cohort (Cohort 2) FFRCT0/104 (0%)1/104 (1%)13/104 (12.5%)
Invasive Cohort (Cohort 1) Usual Care1/187 (0.5%)6/187 (3.2%)137/187 (73.3%)
Invasive Cohort (Cohort 1) FFRCT0/193 (0%)9/193 (4.7%)24/193 (12.4%)
Most frequent serious events
Most frequent serious events
EventNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTInvasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCT
MACE or vascular complicationsCardiac disorders1/1001/1044/1877/193
Nonfatal MICardiac disorders1/1000/1041/1871/193
All-cause deathCardiac disorders0/1000/1041/1870/193
Hospitalization with urgent revascularizationCardiac disorders0/1000/1040/1871/193
Most frequent other events
Most frequent other events
EventNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTInvasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCT
Invasive catheterization without obstructive CADCardiac disorders6/10013/104137/18724/193

Baseline characteristics

Age, Continuous
Age, Continuous(years)Invasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCTNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTTotal
Mean63.36 ± 10.9360.72 ± 10.2057.91 ± 10.7259.48 ± 9.3360.86 ± 10.54
Sex: Female, Male
Sex: Female, Male(Participants)Invasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCTNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTTotal
Female79743444231
Male1081196660353
Diabetes
Diabetes(Participants)Invasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCTNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTTotal
Count of participants36308680
Current smoker
Current smoker(Participants)Invasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCTNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTTotal
Count of participants42382223125
Hypertension
Hypertension(Participants)Invasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCTNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTTotal
Count of participants1111113857317
Hyperlipidemia
Hyperlipidemia(Participants)Invasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCTNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTTotal
Count of participants76772228203
Atypical angina
Atypical angina(Participants)Invasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCTNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTTotal
Count of participants1221429180435
Prior noninvasive testing
Prior noninvasive testing(Participants)Invasive Cohort (Cohort 1) Usual CareInvasive Cohort (Cohort 1) FFRCTNon-invasive (Cohort 2) Usual CareNon-invasive Cohort (Cohort 2) FFRCTTotal
Count of participants9210005197

1 further baseline measures are reported on the registry.

08

Study locations

15 sites
  • HeartFlow, Inc
    Redwood City, California 94063, United States
  • Stanford University
    Stanford, California 94305, United States
  • Duke University Clinical Research Institution
    Durham, North Carolina 27705, United States
  • LKH-GRAZ-West - Department of Cardiology
    Graz, A-8020, Austria
  • Innsbruck Medical University, Department of Radiology II
    Innsbruck, A-6020, Austria
  • Cardiovascular Center Aalst
    Aalst, Belgium
  • Aarhus University Hospital Skejby
    Aarhus, 8200, Denmark
  • CHU Brest - Hopital de Cardiologie
    Brest, 29609, France
  • Cardiovascular Hospital -Interventional Cardiology Dept, Hospices Civils de Lyon and Claude Bernard University France
    Lyon, 69677, France
  • Heart Center Leipzig GmbH
    Leipzig, 04289, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
  • Deutsches Herzzentrum München - ISAResearch Centre
    Munich, 80636, Germany
  • Centro Cardiologico Monzino
    Milan, 20154, Italy
  • Freeman Hospital - Therapeutics & Cardiac Research Team
    Newcastle upon Tyne, NE7 7DN, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Douglas PS, De Bruyne B, Pontone G, Patel MR, Norgaard BL, Byrne RA, Curzen N, Purcell I, Gutberlet M, Rioufol G, Hink U, Schuchlenz HW, Feuchtner G, Gilard M, Andreini D, Jensen JM, Hadamitzky M, Chiswell K, Cyr D, Wilk A, Wang F, Rogers C, Hlatky MA; PLATFORM Investigators. 1-Year Outcomes of FFRCT-Guided Care in Patients With Suspected Coronary Disease: The PLATFORM Study. J Am Coll Cardiol. 2016 Aug 2;68(5):435-445. doi: 10.1016/j.jacc.2016.05.057. PubMed 27470449 ↗
  • Hlatky MA, De Bruyne B, Pontone G, Patel MR, Norgaard BL, Byrne RA, Curzen N, Purcell I, Gutberlet M, Rioufol G, Hink U, Schuchlenz HW, Feuchtner G, Gilard M, Andreini D, Jensen JM, Hadamitzky M, Wilk A, Wang F, Rogers C, Douglas PS; PLATFORM Investigators. Quality-of-Life and Economic Outcomes of Assessing Fractional Flow Reserve With Computed Tomography Angiography: PLATFORM. J Am Coll Cardiol. 2015 Dec 1;66(21):2315-2323. doi: 10.1016/j.jacc.2015.09.051. Epub 2015 Oct 14. PubMed 26475205 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2025, 9 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2013
First posted
Sep 17, 2013
Start
Sep 2013
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Sep 5, 2025
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01943903
Lead sponsor
HeartFlow, Inc.
Collaborators
Duke Clinical Research Institute
Responsible party
Sponsor
First posted
Sep 17, 2013
Start date
Sep 2013
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Sep 5, 2025
Last update
Sep 5, 2025

Study contacts

Gianluca Pontone, MD
principal investigator · Centro Cardiologico Monzino
Pamela Douglas, MD
principal investigator · Duke University
Bernard de Bruyne, MD, PHD
principal investigator · Cardiovascular Center Aalst
Mark Hlatky, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion